This record was last updated August 20, 2024 (before its estimated September 2025 completion). Its status may not reflect the trial's current state.
Summary
Gingival recession is a common defect among the American population. It is also a major cause for root decay, hypersensitivity, contributes to tooth mobility and low self-esteem. Acellular dermal matrix, a human-derived grafting material has been put on the market for the treatment of gingival recession. Treating gingival recession with this material has been a validated treatment option for years.
However, treatment outcomes in two patient populations, namely those with thin biotypes and those with thick biotypes, has not been investigated. This study will observe the primary treatment outcomes in the two patient groups at 5 time points - 3 months, 6 months and 12 months post-surgery to observe short term outcomes; additional 24 months and 48 months post-surgery to observe long term outcomes.
Protocol Amendment History
5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2017-02-15; most recent amendment 2024-08-16.
Status change: Recruiting → Active, Not Recruiting2020-03-10